Cognitive Behavioral Therapy App for Cancer Pain

(STAMP+CBT Trial)

Recruiting in Palo Alto (17 mi)

Overseen by Desiree Azizoddin, PsyD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of Oklahoma

No Placebo Group

Approved in 4 Jurisdictions

Trial Summary

What is the purpose of this trial?

This trial tests the STAMP+CBT app, a smartphone tool for advanced cancer patients to manage pain and mood. It tracks health metrics and provides personalized advice and educational content to improve pain management.

Eligibility Criteria

This trial is for adults over 18 with advanced cancer experiencing chronic pain (pain score >4) and using opioids to manage it. They must be undergoing treatment or receiving supportive care, not in remission, hospice, or hospitalized. Excludes those with cognitive impairments affecting participation, non-English speakers, recent surgery patients, and individuals under opioid risk mitigation programs.

Inclusion Criteria

I am currently prescribed opioids for my cancer pain.

I have an advanced cancer diagnosis and am currently receiving treatment or supportive care.

My cancer or its treatment causes me significant pain.

Exclusion Criteria

You are currently receiving hospice care.

I am an adult capable of giving consent, not pregnant, and not incarcerated.

My main pain is from a surgery I had within the last 2 weeks.

Participant Groups

The study tests a new smartphone app called STAMP+CBT designed to help track pain levels, mood changes, opioid use and side effects while providing personalized education and self-management tips for managing cancer-related pain.

Group I: STAMP+CBT app Experimental Treatment 1 Intervention

This app will allow the patient to access daily surveys designed to assess pain, stress, mood, and related symptoms. Based on patient-reported symptoms, this app will disseminate tailored education to manage the symptoms.

Cognitive Behavioral Therapy is already approved in European Union, United States, Canada, Australia for the following indications:

🇪🇺 Approved in European Union as Cognitive Behavioral Therapy for:

• Anxiety disorders
• Depressive disorders
• Eating disorders
• Post-traumatic stress disorder (PTSD)
• Obsessive-compulsive disorder (OCD)

🇺🇸 Approved in United States as Cognitive Behavioral Therapy for:

• Anxiety disorders
• Depressive disorders
• Eating disorders
• Post-traumatic stress disorder (PTSD)
• Obsessive-compulsive disorder (OCD)
• Substance use disorders

🇨🇦 Approved in Canada as Cognitive Behavioral Therapy for:

• Anxiety disorders
• Depressive disorders
• Eating disorders
• Post-traumatic stress disorder (PTSD)
• Obsessive-compulsive disorder (OCD)

🇦🇺 Approved in Australia as Cognitive Behavioral Therapy for:

• Anxiety disorders
• Depressive disorders
• Eating disorders
• Post-traumatic stress disorder (PTSD)
• Obsessive-compulsive disorder (OCD)

Find a Clinic Near You

Research Locations Nearby Select from list below to view details:

University of Oklahoma Health Sciences Center Oklahoma City, OK

Who Is Running the Clinical Trial?

University of Oklahoma Lead Sponsor

National Cancer Institute (NCI) Collaborator

References